Ruth Oltenfreiter

531 total citations
25 papers, 438 citations indexed

About

Ruth Oltenfreiter is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Ruth Oltenfreiter has authored 25 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Cancer Research and 9 papers in Molecular Biology. Recurrent topics in Ruth Oltenfreiter's work include Peptidase Inhibition and Analysis (9 papers), Protease and Inhibitor Mechanisms (9 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Ruth Oltenfreiter is often cited by papers focused on Peptidase Inhibition and Analysis (9 papers), Protease and Inhibitor Mechanisms (9 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Ruth Oltenfreiter collaborates with scholars based in Belgium, Netherlands and Italy. Ruth Oltenfreiter's co-authors include Christophe Van de Wiele, Guido Slegers, Ludovicus Staelens, Matteo Zanda, K. Maskos, Athanasios Yiotakis, Vincent Dive, Peter Goettig, Wolfram Bode and Robert Huber and has published in prestigious journals such as Journal of Molecular Biology, Current Pharmaceutical Design and European Journal of Nuclear Medicine and Molecular Imaging.

In The Last Decade

Ruth Oltenfreiter

25 papers receiving 430 citations

Peers

Countries citing papers authored by Ruth Oltenfreiter

Since Specialization

Citations

This map shows the geographic impact of Ruth Oltenfreiter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Oltenfreiter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Oltenfreiter more than expected).

Fields of papers citing papers by Ruth Oltenfreiter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Oltenfreiter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Oltenfreiter. The network helps show where Ruth Oltenfreiter may publish in the future.

Co-authorship network of co-authors of Ruth Oltenfreiter

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Oltenfreiter. A scholar is included among the top collaborators of Ruth Oltenfreiter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Oltenfreiter. Ruth Oltenfreiter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Probes for Non-invasive Matrix Metalloproteinase-targeted Imaging with PET and SPECT 2013 ·Current Pharmaceutical Design ·(unknown), Aren van Waarde, Rainer Bischoff, Ruth Oltenfreiter, Christophe Van de Wiele, Rudi Dierckx, Philip H. Elsinga	55
2	Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital 2011 ·European Journal of Nuclear Medicine and Molecular Imaging ·Bieke Lambert, Emiel J.C. Sturm, (unknown), Ruth Oltenfreiter, Peter Smeets, Roberto Troisi, Hans Van Vlierberghe, Luc Defreyne	22
3	In Vivo Imaging of Apoptosis in Oncology: An Update 2011 ·Molecular Imaging ·Christel Vangestel, Marc Peeters, Gilles Mees, Ruth Oltenfreiter, Hendrikus H. Boersma, Philip H. Elsinga, Chris Reutelingsperger, Nancy Van Damme, Bart De Spiegeleer, Christophe Van de Wiele	28
4	Membrane Type 1 Matrix Metalloproteinase Detection in Tumors, Using the Iodinated Endogenous [ ¹²³ I]-Tissue Inhibitor 2 of Metalloproteinases as Imaging Agent 2010 ·Cancer Biotherapy and Radiopharmaceuticals ·(unknown), Ruth Oltenfreiter, Françis Frankenne, (unknown), Erik Maquoi, Agnès Noël, Jean‐Michel Foidart, Christophe Van de Wiele, Filip De Vos	7
5	In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells 2010 ·Nuclear Medicine and Biology ·Christel Vangestel, Marc Peeters, Ruth Oltenfreiter, Yves D’Asseler, Steven Staelens, (unknown), Jan Philippé, Dennis H. M. Kusters, Chris Reutelingsperger, Nancy Van Damme, Christophe Van de Wiele	16
6	Crystal Structures of MMP-9 Complexes with Five Inhibitors: Contribution of the Flexible Arg424 Side-chain to Selectivity 2007 ·Journal of Molecular Biology ·(unknown), K. Maskos, Robert Huber, Ruth Oltenfreiter, Vincent Dive, Athanasios Yiotakis, Matteo Zanda, Wolfram Bode, Peter Goettig	126
7	Update: Imaging Probes Targeting Matrix Metalloproteinases 2006 ·Cancer Biotherapy and Radiopharmaceuticals ·Christophe Van de Wiele, Ruth Oltenfreiter	25
8	Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents 2006 ·Applied Radiation and Isotopes ·Ruth Oltenfreiter, Ludovicus Staelens, Veerle Kersemans, Bart Cornelissen, Françis Frankenne, Jean‐Michel Foidart, Christophe Van de Wiele, Guido Slegers	12
9	Tryptophane-Based Biphenylsulfonamide Matrix Metalloproteinase Inhibitors as Tumor Imaging Agents 2005 ·Cancer Biotherapy and Radiopharmaceuticals ·Ruth Oltenfreiter, Ludovicus Staelens, Soraya Labied, Veerle Kersemans, Françis Frankenne, Agnès Noël, Christophe Van de Wiele, Guido Slegers	14
10	Synthesis, quality control and in vivo evaluation of [¹²³I] rhTIMP‐2, a potential tumour‐imaging agent 2005 ·Journal of Labelled Compounds and Radiopharmaceuticals ·Ruth Oltenfreiter, Ingrid J.G. Burvenich, Ludovicus Staelens, Annabelle Lejeune, Françis Frankenne, Jean‐Michel Foidart, Guido Slegers	3
11	Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor 2005 ·Nuclear Medicine Communications ·Bart Cornelissen, Veerle Kersemans, Ingrid J.G. Burvenich, Ruth Oltenfreiter, Jean‐Luc Vanderheyden, Otto C. Boerman, (unknown), Guido Slegers	7
12	In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker 2005 ·Nuclear Medicine and Biology ·Bart Cornelissen, Ruth Oltenfreiter, Veerle Kersemans, Ludovicus Staelens, Françis Frankenne, Jean-Michel Foidart, Guido Slegers	25
13	In vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide: a potential sigma receptor ligand for SPECT studies 2005 ·Nuclear Medicine and Biology ·Ludovicus Staelens, Ruth Oltenfreiter, Filip Dumont, Rikki N. Waterhouse, (unknown), Peter Blanckaert, Rudi Dierckx, Guido Slegers	7
14	Comparison between 1 T MRI and non-MRI based volumetry in inoculated tumours in mice 2005 ·British Journal of Radiology ·Bart Cornelissen, Veerle Kersemans, (unknown), Ludovicus Staelens, Ruth Oltenfreiter, (unknown), Eric Achten, Guido Slegers	9
15	Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents 2005 ·Applied Radiation and Isotopes ·Ruth Oltenfreiter, Ludovicus Staelens, Ulrik Hillaert, (unknown), Agnès Noël, Françis Frankenne, Guido Slegers	8
16	123I-EGF internalisation in tumour cells in vitro is inhibited by farnesyltransferase inhibitor therapy: possible target for early therapy response prediction 2004 ·Ghent University Academic Bibliography (Ghent University) ·Bart Cornelissen, Katrien Remaut, Veerle Kersemans, Ruth Oltenfreiter, Ingrid J.G. Burvenich, Guido Slegers	2
17	New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents 2004 ·Nuclear Medicine and Biology ·Ruth Oltenfreiter, Ludovicus Staelens, Annabelle Lejeune, Filip Dumont, Françis Frankenne, Jean‐Michel Foidart, Guido Slegers	23
18	Synthesis and assessment of [11C]acetylhomotaurine as an imaging agent for the study of the pharmacodynamic properties of acamprosate by positron emission tomography 2004 ·Nuclear Medicine and Biology ·(unknown), Bart Cornelissen, Ruth Oltenfreiter, (unknown), Guido Slegers, K. Strijckmans	10
19	Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging 2002 ·European Journal of Nuclear Medicine and Molecular Imaging ·Christophe Van de Wiele, Ruth Oltenfreiter, O. C. Winter, Alberto Signore, Guido Slegers, Rudi Dierckx	26
20	Title: Synthesis, biodistribution and blocking studies in mice of a new 123I-labeled dopamine D3 antagonist Dierckx RA, Slegers G 2001 ·Ghent University Academic Bibliography (Ghent University) ·Ludovicus Staelens, Filip Dumont, (unknown), Ruth Oltenfreiter, (unknown), Ingeborg Goethals, Rudi Dierckx, Guido Slegers	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact